{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:58:09Z","timestamp":1782845889328,"version":"3.54.5"},"reference-count":60,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The growing importance of real-world data (RWD) as a source of evidence for drug effects has led to increased interest in clinical research utilizing secondary use data from electronic medical record systems. Although immune checkpoint inhibitors and targeted therapies have advanced lung cancer treatment, managing complications such as interstitial lung disease (ILD) remains challenging. Early detection and prevention of ILD are crucial for improving patient prognosis and quality of life; however, predictive biomarkers have yet to be established. Therefore, methods to identify ILD risk factors and enable early detection using RWD are needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This exploratory study aimed to identify associated factors and prodromal symptoms of ILD onset using clinical data stored in a hospital information system.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Clinical data of patients diagnosed with stage IV lung cancer between November 2011 and December 2018 were extracted from the hospital information system of the National Cancer Center Hospital in Japan. A total of 3 patient groups were defined: the ILD Set, based on laboratory test results and radiological records; the ILD-GC Set, which added glucocorticoid treatment to the ILD Set; and the No ILD Set, for patients without ILD. The primary endpoint was the frequency of Japanese words extracted from electronic medical records, specifically from notes in the Problem-Oriented System\/Subjective, Objective, Assessment and Plan format. Noun frequencies were compared between the ILD or ILD-GC Sets and the No ILD Set. Free-text data were processed using morphological analysis, and terms were categorized using the Patient Disease Expression Dictionary or the World Health Organization Drug Dictionary. Key terms were extracted from physician and nurse records based on the descending order of ranking differences to identify associated factors and prodromal symptoms.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The analysis included 674 cases (105 in the ILD Set [including 12 in the ILD-GC Set] and 569 in the No ILD Set). Baseline characteristics showed no apparent differences across groups. In the 30 days prior to ILD onset, notable differences in word frequencies per 1000 notes between the ILD-GC Set and No ILD Set were observed in the following term categories: respiratory symptoms (eg, breathlessness, shortness of breath, oxygen), ranging from 170.59 to 46.51; pain or analgesics (eg, Lyrica [pregabalin], soreness, precordial pain, opioids), ranging from 462.88 to 45.16; and appetite-related terms (eg, inappetence, food intake, queasiness, Novamin [prochlorperazine]), ranging from 102.23 to 51.90.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Terms related to respiratory symptoms, pain or analgesics, and appetite were identified as associated factors for ILD onset in patients with stage IV lung cancer using RWD from acute care institutions for malignant tumors. These findings may support the early detection of ILD and underscore the potential of RWD to generate real-world evidence that informs drug discovery and pharmaceutical development.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/70603","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:11:21Z","timestamp":1762204281000},"page":"e70603-e70603","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Terminologies Used Prior to the Onset of Interstitial Lung Disease in Patients With Lung Cancer: Descriptive Analysis of Electronic Medical Record Data"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-6078","authenticated-orcid":false,"given":"Masami","family":"Mukai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5785-5230","authenticated-orcid":false,"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3709-7504","authenticated-orcid":false,"given":"Tomohiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8321-1113","authenticated-orcid":false,"given":"Ryunosuke","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-0323","authenticated-orcid":false,"given":"Yasuo","family":"Sugitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8779-462X","authenticated-orcid":false,"given":"Yoshimasa","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1757-1475","authenticated-orcid":false,"given":"Noriaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-3178","authenticated-orcid":false,"given":"Naoki","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R1","unstructured":"Food and Drug Administration. Real-world evidence. 2023. URL: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence [Accessed 03-06-2024]"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","article-title":"Real-world data for regulatory decision making: challenges and possible solutions for Europe","volume":"106","author":"Cave","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"R3","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research","volume":"30","author":"Tang","journal-title":"Curr Oncol"},{"issue":"4","key":"R4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/jamia\/ocy173","article-title":"Natural language processing of symptoms documented in free-text narratives of electronic health records: a systematic review","volume":"26","author":"Koleck","journal-title":"J Am Med Inform Assoc"},{"key":"R5","volume":"42","author":"Nakajima","journal-title":"Jpn J Med Inform"},{"issue":"3","key":"R6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"R7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"R8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl_4","key":"R9","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","journal-title":"Ann Oncol"},{"issue":"4","key":"R10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","journal-title":"Ann Oncol"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","journal-title":"Ann Oncol"},{"issue":"7","key":"R12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","journal-title":"Ann Oncol"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","journal-title":"N Engl J Med"},{"issue":"19","key":"R14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","journal-title":"N Engl J Med"},{"issue":"20","key":"R15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","journal-title":"N Engl J Med"},{"issue":"22","key":"R16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","journal-title":"N Engl J Med"},{"issue":"23","key":"R17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","journal-title":"N Engl J Med"},{"issue":"24","key":"R18","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","journal-title":"N Engl J Med"},{"issue":"10089","key":"R19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","journal-title":"The Lancet"},{"issue":"23","key":"R20","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","journal-title":"J Clin Oncol"},{"issue":"9","key":"R21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","journal-title":"N Engl J Med"},{"issue":"8","key":"R22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","journal-title":"N Engl J Med"},{"issue":"2","key":"R23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","journal-title":"N Engl J Med"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","journal-title":"Lancet Oncol"},{"issue":"2","key":"R25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","journal-title":"Lancet Oncol"},{"issue":"5","key":"R26","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21037\/jtd-22-93","article-title":"Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management","volume":"14","author":"Kim","journal-title":"J Thorac Dis"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1179\/1973947814Y.0000000189","article-title":"Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials","volume":"27","author":"Qi","journal-title":"J Chemother"},{"issue":"10354","key":"R28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","journal-title":"Lancet"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1378\/chest.96.1.68","article-title":"New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6","volume":"96","author":"Kohno","journal-title":"Chest"},{"issue":"6 Pt 1","key":"R30","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1164\/ajrccm.152.6.8520747","article-title":"Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids","volume":"152","author":"Honda","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"R31","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-78","article-title":"Serum biomarkers in interstitial lung diseases","volume":"6","author":"Tzouvelekis","journal-title":"Respir Res"},{"issue":"Suppl 2","key":"R32","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1038\/sj.bjc.6602065","article-title":"Understanding the mechanisms of drug-associated interstitial lung disease","volume":"91 Suppl 2","author":"Higenbottam","journal-title":"Br J Cancer"},{"issue":"10","key":"R33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","journal-title":"J Clin Med"},{"key":"R34","unstructured":"Astra Zeneca. A non interventional pilot study on machine learning for ILD detection based on the patient data from digital devices in unresectable stage III non-small cell lung cancer patients receiving durvalumab (idetect). URL: https:\/\/clinicaltrials.gov\/study\/NCT04884269 [Accessed 31-05-2024]"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.20892\/j.issn.2095-3941.2023.0036","article-title":"The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan","volume":"21","author":"Yoshida","journal-title":"Cancer Biol Med"},{"issue":"4","key":"R36","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.421","article-title":"Screening of anticancer drugs to detect drug-induced interstitial pneumonia using the accumulated data in the electronic medical record","volume":"6","author":"Shimai","journal-title":"Pharmacol Res Perspect"},{"key":"R37","volume":"40","author":"Mukai","journal-title":"Jpn J Med Inform"},{"key":"R38","volume":"41","author":"Mukai","journal-title":"Jpn J Med Inform"},{"issue":"13_Supplement","key":"R39","doi-asserted-by":"publisher","first-page":"B006","DOI":"10.1158\/1557-3265.AIMACHINE-B006","article-title":"Abstract B006: using large language models for scalable extraction of real-world progression events across multiple cancer types","volume":"31","author":"Cohen","journal-title":"Clin Cancer Res"},{"key":"R40","author":"Kudo","journal-title":"Association for Computational Linguistics"},{"issue":"6","key":"R41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.14948\/jami.32.301","article-title":"Comparative evaluation of ComeJisyo V1, ComeJisyo V2 and ComeJisyo V3 (Article in Japanese)","volume":"32","author":"Sagara","journal-title":"Jpn J Med Inform"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.11517\/jsaisigtwo.2021.AIMED-011_04","article-title":"Patient expression normalization based on generative approach","author":"Nishidani","journal-title":"Jpn Soc Artif Intell Spec Interest Group Type 2"},{"key":"R43","unstructured":"Uppsala Monitoring Centre. WHODrug standardised drug groupings (SDGs). 2024. URL: https:\/\/who-umc.org\/whodrug\/whodrug-standardised-drug-groupings-sdgs\/ [Accessed 31-05-2024]"},{"key":"R44","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). Medical Dictionary for Regulatory Activities (MedDRA); version 27.1. 2024. URL: https:\/\/www.meddra.org\/ [Accessed 30-10-2025]"},{"key":"R45","unstructured":"Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare; Ministry of Economy, Trade and Industry. Ethical Guidelines for Medical and Biological Research Involving Human Subjects. 2021. URL: https:\/\/www.mext.go.jp\/content\/20250325-mxt_life-000035486-01.pdf [Accessed 23-10-2025]"},{"issue":"6","key":"R46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"R47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","journal-title":"BMJ Open"},{"issue":"4","key":"R48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jcpt.12683","article-title":"Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database","volume":"43","author":"Kose","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"R49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.resinv.2018.06.002","article-title":"Ethnic differences in idiopathic pulmonary fibrosis: the Japanese perspective","volume":"56","author":"Saito","journal-title":"Respir Investig"},{"issue":"8","key":"R50","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non\u2013small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","journal-title":"J Thorac Oncol"},{"issue":"2","key":"R51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/resp.12665","article-title":"Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study","volume":"21","author":"Hamada","journal-title":"Respirology"},{"issue":"3","key":"R52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.25259\/IJPC_368_20","article-title":"Identifying the needs based on the patients\u2019 performance status for palliative care team: an observational study","volume":"27","author":"Sakamoto","journal-title":"Indian J Palliat Care"},{"key":"R53","unstructured":"Satomi E Amano K Ishiki H Kiuchi D Abe A Kobayashi Y et al. Annual report 2023. Department of Palliative Medicine, National Cancer Center Hospital. URL: https:\/\/www.ncc.go.jp\/en\/ncch\/clinic\/palliative_care\/Palliative_Medicine\/index.html [Accessed 13-02-2024]"},{"issue":"5","key":"R54","doi-asserted-by":"publisher","first-page":"728","DOI":"10.21037\/apm.2019.09.14","article-title":"Management of altered mental status and delirium in cancer patients","volume":"8","author":"El Majzoub","journal-title":"Ann Palliat Med"},{"issue":"2","key":"R55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejcsup.2013.07.008","article-title":"Drug-associated delirium in cancer patients","volume":"11","author":"Caraceni","journal-title":"EJC Suppl"},{"issue":"6","key":"R56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003870.pub7","article-title":"Oxycodone for cancer-related pain","volume":"6","author":"Schmidt-Hansen","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"R57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.04.014","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer","volume":"71","author":"Reyes-Habito","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"R58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajh.23628","article-title":"Diagnosis and treatment of cancer-related anemia","volume":"89","author":"Gilreath","journal-title":"Am J Hematol"},{"issue":"2","key":"R59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: a review","volume":"7","author":"Johnstone","journal-title":"Ann Palliat Med"},{"issue":"1380358","key":"R60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380358","article-title":"Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches","volume":"14","author":"Bozzini","journal-title":"Front Oncol"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2025\/1\/e70603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:59:26Z","timestamp":1782842366000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2025\/1\/e70603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2196\/70603","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"v11i1e70603"}}